Published in J Oral Pathol Med on July 01, 2004
A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2010) 1.89
The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest (2012) 1.86
FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One (2009) 1.48
Current aspects on oral squamous cell carcinoma. Open Dent J (2012) 1.47
Oral premalignancy: new methods of detection and treatment. Curr Oncol Rep (2006) 1.09
Optical molecular imaging of epidermal growth factor receptor expression to improve detection of oral neoplasia. Neoplasia (2009) 0.99
Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas. Oncotarget (2014) 0.96
TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors. J Transl Med (2013) 0.92
Targeted inhibition of CD133+ cells in oral cancer cell lines. J Dent Res (2011) 0.88
Oral field cancerization: current evidence and future perspectives. Oral Maxillofac Surg (2012) 0.88
Optical molecular imaging of multiple biomarkers of epithelial neoplasia: epidermal growth factor receptor expression and metabolic activity in oral mucosa. Transl Oncol (2012) 0.87
The translational significance of epithelial-mesenchymal transition in head and neck cancer. Clin Transl Med (2014) 0.86
Genomic aberrations in normal appearing mucosa fields distal from oral potentially malignant lesions. Cell Oncol (Dordr) (2011) 0.86
Alterations in Cell-Extracellular Matrix Interactions during Progression of Cancers. Int J Cell Biol (2012) 0.86
Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes Dis (2014) 0.83
Oral premalignant lesions: from the pathological viewpoint. Int J Clin Oncol (2011) 0.82
Investigation of the potential of Raman spectroscopy for oral cancer detection in surgical margins. Lab Invest (2015) 0.81
Evidence that alpha-9 human papillomavirus infections are a major etiologic factor for oropharyngeal carcinoma in black South Africans. Head Neck Pathol (2013) 0.80
Downregulation of miRNA-424: a sign of field cancerisation in clinically normal tongue adjacent to squamous cell carcinoma. Br J Cancer (2015) 0.79
Topical Application of Green Tea Polyphenol (-)-Epigallocatechin-3-gallate (EGCG) for Prevention of Recurrent Oral Neoplastic Lesions. J Orofac Sci (2012) 0.76
Fat-1 gene inhibits human oral squamous carcinoma cell proliferation through downregulation of β-catenin signaling pathways. Exp Ther Med (2015) 0.76
Open questions in oesophageal adenocarcinogenesis. Gut (2007) 0.76
Serum lipid profile in oral submucous fibrosis: A clinico pathological study. J Oral Maxillofac Pathol (2015) 0.75
Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer. Oncotarget (2016) 0.75
p53: Revealing the Unusual Suspect: a Study and Field Cancerization Minireview. Indian J Surg Oncol (2014) 0.75
Histologic and immunohistochemical evaluation of mirror image biopsies in oral squamous cell carcinoma. J Oral Biol Craniofac Res (2016) 0.75
ALDH1 and podoplanin expression patterns predict the risk of malignant transformation in oral leukoplakia. Oncol Lett (2016) 0.75
Gene expression changes in tumor free tongue tissue adjacent to tongue squamous cell carcinoma. Oncotarget (2016) 0.75
The molecular biology of head and neck cancer. Nat Rev Cancer (2010) 9.84
Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer (2008) 7.99
Dissecting the metastatic cascade. Nat Rev Cancer (2004) 6.32
A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res (2003) 5.04
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst (2004) 3.67
BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Res (2006) 3.32
Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res (2006) 2.71
Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol (2007) 2.47
Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys (2008) 2.13
Oral malignant melanoma: a review of the literature. Oral Oncol (2006) 1.70
Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med (2009) 1.68
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med (2006) 1.62
(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med (2005) 1.56
Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel lymph node. Eur J Nucl Med Mol Imaging (2012) 1.49
Selective neck dissection in the management of the neck after (chemo)radiotherapy for advanced head and neck cancer. Proposal for a classification update. Head Neck (2010) 1.42
Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral Oncol (2009) 1.41
Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck (2002) 1.41
Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med (2013) 1.40
Primary lung cancer after treatment of head and neck cancer without lymph node metastasis: is there a role for autofluorescence bronchoscopy? Lung Cancer (2008) 1.39
Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer (2005) 1.39
Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging (2002) 1.36
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging (2008) 1.36
Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst (2008) 1.36
Advances and applications of oral cancer basic research. Oral Oncol (2011) 1.33
Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer (2012) 1.31
Predictive modelling for swallowing dysfunction after primary (chemo)radiation: results of a prospective observational study. Radiother Oncol (2011) 1.31
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res (2006) 1.30
A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol (2009) 1.28
Elective and therapeutic selective neck dissection. Oral Oncol (2005) 1.26
Quality of life and functional status in patients with cancer of the oral cavity and oropharynx: pretreatment values of a prospective study. Eur Arch Otorhinolaryngol (2007) 1.24
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther (2008) 1.24
Management of Frey syndrome. Head Neck (2007) 1.24
Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res (2004) 1.24
CGHMultiArray: exact P-values for multi-array comparative genomic hybridization data. Bioinformatics (2005) 1.23
Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am J Pathol (2002) 1.20
Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin Cancer Biol (2005) 1.20
Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res (2009) 1.19
Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res (2004) 1.18
Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial. Radiother Oncol (2008) 1.17
Neck dissection: then and now. Auris Nasus Larynx (2006) 1.14
Human papilloma virus in head and neck cancer: the need for a standardised assay to assess the full clinical importance. Eur J Cancer (2009) 1.14
Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.14
Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. J Pathol (2003) 1.13
Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma. Int J Cancer (2003) 1.12
The psychometric and clinical validity of the SWAL-QOL questionnaire in evaluating swallowing problems experienced by patients with oral and oropharyngeal cancer. Oral Oncol (2009) 1.12
Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients. Cancer Res (2005) 1.12
Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol (2002) 1.11
Post-traumatic cutaneous meningioma. J Laryngol Otol (2004) 1.11
Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck (2008) 1.11
Quality of life after surgical treatment for oral and oropharyngeal cancer: a prospective longitudinal assessment of patients reconstructed by a microvascular flap. Oral Oncol (2007) 1.10
Computerized prospective screening for high levels of emotional distress in head and neck cancer patients and referral rate to psychosocial care. Oral Oncol (2009) 1.10
Genetic classification of oral and oropharyngeal carcinomas identifies subgroups with a different prognosis. Cell Oncol (2009) 1.10
Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res (2011) 1.08
Management of adult soft tissue sarcomas of the head and neck. Oral Oncol (2010) 1.08
Genetic reprogramming of tumor cells by zinc finger transcription factors. Proc Natl Acad Sci U S A (2005) 1.07
High-risk human papillomavirus-positive lung cancer: molecular evidence for a pattern of pulmonary metastasis. J Thorac Oncol (2013) 1.06
Prognostic factors in adult soft tissue sarcomas of the head and neck: a single-centre experience. Oral Oncol (2006) 1.06
A noninvasive genetic screening test to detect oral preneoplastic lesions. Lab Invest (2005) 1.06
Effect of nutritional interventions on nutritional status, quality of life and mortality in patients with head and neck cancer receiving (chemo)radiotherapy: a systematic review. Clin Nutr (2013) 1.06
Chest CT and whole-body 18F-FDG PET are cost-effective in screening for distant metastases in head and neck cancer patients. J Nucl Med (2010) 1.05
Adenoid cystic carcinoma of the head and neck: a single-center analysis of 105 consecutive cases over a 30-year period. Oral Oncol (2013) 1.05
Proposal for a rational classification of neck dissections. Head Neck (2010) 1.04
Cordectomy by CO2 laser or radiotherapy for small T1a glottic carcinomas: costs, local control, survival, quality of life, and voice quality. Head Neck (2007) 1.04
Modern reconstruction techniques for oral and pharyngeal defects after tumor resection. Eur Arch Otorhinolaryngol (2007) 1.04
Flap reconstruction of the hypopharynx: a defect orientated approach. Acta Otorhinolaryngol Ital (2012) 1.01
Second field tumors: a new opportunity for cancer prevention? Oncologist (2005) 1.01
Prospective evaluation of health-related quality of life in long-term oral and oropharyngeal cancer survivors and the perceived need for supportive care. Oral Oncol (2013) 1.01
Comorbid condition as a prognostic factor for complications in major surgery of the oral cavity and oropharynx with microvascular soft tissue reconstruction. Head Neck (2003) 1.01
Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990-2009). Int J Cancer (2013) 1.01
Primary treatment of the anterior vocal commissure squamous carcinoma. Eur Arch Otorhinolaryngol (2006) 0.99
Speech Handicap Index in patients with oral and pharyngeal cancer: better understanding of patients' complaints. Head Neck (2008) 0.99
DNA quality assessment for array CGH by isothermal whole genome amplification. Cell Oncol (2007) 0.99
Oral malignant melanoma: the amsterdam experience. J Oral Maxillofac Surg (2007) 0.99
Protein biomarker discovery for head and neck cancer. J Proteomics (2010) 0.99
(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging (2009) 0.99
Detecting recurrent laryngeal carcinoma after radiotherapy: room for improvement. Eur Arch Otorhinolaryngol (2003) 0.99
Screening for distant metastases in patients with head and neck cancer: is chest computed tomography sufficient? Laryngoscope (2005) 0.98
Employment and return to work in head and neck cancer survivors. Oral Oncol (2009) 0.98
Improving access to supportive cancer care through an eHealth application: a qualitative needs assessment among cancer survivors. J Clin Nurs (2015) 0.98